Wow...Studio nuovo che utilizza i cellule staminali del cordone ombelicale

Dear Families of Cord Blood Registry,

A new clinical trial starting enrollment this month will attempt to reverse hearing
loss in children. The trial, being conducted at Children's Memorial Hermann
Hospital, is the first FDA-regulated study exploring the use of cord blood stem
cells to repair sensorineural hearing loss.

Sensorineural hearing loss affects approximately 6 per 1000 children, with 9%
resulting from acquired causes such as viral infection and head injury.1,2,3 Most of
the time, sensorineural hearing loss cannot be medically or surgically corrected.4

In this new clinical trial, however, researchers are evaluating the safety of cord
blood stem cells as a potential reparative treatment option for hearing loss in
children.

According to Dr. James Baumgartner, M.D., lead investigator of the study and
pediatric neurosurgeon at Children's Memorial Hermann Hospital, "Children only have
18 months to acquire language skills and, if a child does not hear well, they will
not acquire the language skills to speak normally."

The study will follow 10 children, aged six weeks to 18 months with acquired or
congenital (but not genetic) hearing loss and who also have access to their own
umbilical cord blood stem cells banked at Cord Blood Registry (CBR). Read more about
the trial here (link below). If you have a child who meets the criteria and are
interested in learning more about the study, click here (link below) and enter the
requested information.

This marks the third such clinical trial where researchers have partnered
exclusively with CBR to focus on the use of children's own cord blood stem cells for
study in neurological applications. To ensure consistency in cord blood stem cell
processing, storage and release for infusion, Memorial Hermann Hospital, the
University of Texas Health Science Center (UTHealth) and the Georgia Health Sciences
University, home of the Medical College of Georgia, have all named CBR as their cord
blood bank partner in their FDA-regulated protocols.

CBR is the only family cord blood bank able to link its clients as potential
clinical trial participants with researchers conducting these studies.
We are committed to keeping you informed. For more information about the trials,
please visit the CBR Center for Regenerative Medicine.

Sincerely,

Heather Brown, M.S., C.G.C.
Vice President, Scientific & Medical Affairs
Cord Blood Registry

http://clinicaltrials.gov/ct2/show/NCT01343394

http://www.cordblood.com/regenerative-medicine/form.asp?ref=hearingloss&mtag=OTI8

References:

1. Bergstrom L, Hemenway WG, Downs MP.A high risk registry to find congenital
deafness.OtolaryngolClin North Am. 1977;4:369-399.
2. Billings KR, Kenna MA. Causes of pediatric sensorineural hearing loss: yesterday
and today. Arch Otolaryngol Head Neck Surg. 1999 May;125(5):517-21.
3. Smith RJ, Bale JF Jr, White KR. Sensorineural hearing loss in children.Lancet.
2005;365(9462):879-890.
4. American Speech Language Hearing Association.Sensorineural Hearing Loss.
Available at: http://www.asha.org/public/hearing/Sensorineural-Hearing-Loss/.

Accessed February 2011

Cord Blood Registry - The Name to Trust

The CBR Center for Regenerative Medicine is a scientific research collaborative
established by Cord Blood Registry â€" in partnership with leading research
institutions from around the world â€" to promote greater scientific understanding
of cord blood stem cells and advance their use to treat life-threatening injuries
and diseases.